. 2012 Jun 5;22(7):1108–1128. doi: 10.1038/cr.2012.87

Table 2. Pharmacological and genetic modulations of the chemokine system mediate disease severity in EAE animal models.

Chemokine or receptor	Modulation or intervention		EAE severity	Ref. no.
Chemokine or receptor	Pharmacological	Genetic	EAE severity	Ref. no.
CCR1		Knockout	Alleviated	²⁴⁸
	Antagonists (2-2-diphenyl-5-(4-chlorophenyl) piperidin-1-yl)valeronitrile; BX 471)		Alleviated	^249,250
CCR2		Knockout	Alleviated	^{251,252,253,254}
	Antibody		Alleviated	²¹¹
CCR5		Knockout	Comparable	²⁵⁵
	Antagonist (TAK-779)		Alleviated	²⁵⁶
CCR6		Knockout	Enhanced	^257,258
		Knockout	Alleviated	^259,260
CCR7		Knockout	Alleviated	²⁶¹
CMKLR1		Knockout	Alleviated	²⁶²
CX3CR1		Knockout	Enhanced	²⁶³
CXCR2	Anti-CXCR2 antiserum	Knockout	Alleviated	²⁶⁴
	Antagonists		Alleviated	²⁶⁵
CXCR3		Knockout	Enhanced	^266,267
	Antagonist (CXCL11(4-79))		Alleviated	²⁶⁸
CXCR4	Antagonist (CXCL12(P2G2))		Alleviated	²⁶⁸
	Antagonist (AMD3100)		Enhanced	²⁶⁹
CCL2		Knockout	Alleviated	²⁷⁰
	Antibody		Alleviated	^236,271
		Transgenic expression	Alleviated	²⁷²
CCL3		Knockout	Comparable	²⁵⁵
	Antibody		Alleviated	^236,271
CCL5	Antibody		Comparable	²³⁶
CCL19/CCL21	Exogenous CCL19/CCL21 treatment		Alleviated	²⁶¹
CXCL10	CXCL10 antibody		Alleviated	²⁷³
	CXCL10 antibody		Enhanced	²⁷⁴
		Knockout	Enhanced	²⁷⁵
CXCL13		Knockout	Alleviated	²⁷⁶